Stroke (CVA) or TIANCT07358169
Mirror Therapy on Motor Recovery and Pain of Hemiparetic Arm
A study testing technique in people with Stroke (CVA) or TIA and Hemiparesis, run by Mansoura University at 1 site in Egypt.
Trial summary
evaluate the effect of mirror therapy on motor recovery and pain of hemiparetic arm post stroke Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Stroke (CVA) or TIA, Hemiparesis
- What is being tested?
- technique
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Nov 2025to Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- First stroke attack (ischemic and haemorrhagic )
- Unilateral stroke with hemiparesis
- Able to understand simple verbal language
Who cannot join
- Severe cognitive impairments.
- Orthopedic or rheumatologic problems restricting upper extremity motor function.
- Contraindications to mirror therapy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Mirror Therapy on Motor Recovery and Pain of Hemiparetic Arm Post Stroke: A Randomized Controlled Trial
evaluate the effect of mirror therapy on motor recovery and pain of hemiparetic arm post stroke
- Conditions
- Stroke (CVA) or TIA, Hemiparesis
- Being tested
- technique, Control
- Medical subject headings
- Stroke, Paresis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
techniqueOther
the participant performs arm exercise behind mirror
ControlOther
the control group receive usual hospital care
| Study group | Role | What they receive |
|---|---|---|
| control | Other | usual hospitl care Receives: Other: Control |
| mirror group | Experimental | Not described Receives: Other: technique; Other: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor Function Assessment
measured by Fugl-Meyer Assessment for upper limb motor function. to describe impairment severity, quantify motor recovery, guide treatment planning, and evaluate outcomes. The scale comprises five domains with a maximum total score of 226 points (Motor 100; Sensation 24; Balance 14; Joint ROM 44; Joint Pain 44).
Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.
Points are divided among the domains as follows:
Motor score: ranges from 0 (hemiplegia) to 100 points (normal motor performance). Divided into 66 points for upper extremity and 34 points for the lower extremity.
Sensation: ranges from 0 to 24 points. Divided into 8 points for light touch and 16 points for position sense.
Balance: ranges from 0 to 14 points. Divided into 6 points for sitting and 8 points for standing.
Measured: 3 weeks
Secondary outcomes (2)
Functional independence
Functional independence (measured by Modified Rankin Scale). it is a 7-point scale (0-6) that measures disability after a stroke or neurological event, assessing the ability to perform daily activities, from no disability (0) to death (6).
The Modified Rankin Scale Grade mRS 0 No symptoms at all
- No significant disability: despite symptoms, able to carry out all usual duties and activities
- Slight disability: unable to perform all previous activities but able to look after own affairs without assistance
- Moderate disability: requiring some help but able to walk without assistance
- Moderately severe disability: unable to walk without assistance and attend to own bodily needs without assistance
- Severe disability: bedridden, incontinence, and requiring constant nursing care and attention
- Death
Measured: 3 weeks
Pain assessment
Pain assessment (measured by Numeric Pain Rating Scale.) it is a 11-point scale (0-10) where patients rate their pain intensity, with 0 meaning no pain and 10 representing the worst imaginable pain.
scoring system 0: No Pain 1-3: Mild Pain 4-6: Moderate Pain 7-10: Severe Pain
Measured: 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start15 Nov 2025
- Primary completion15 Feb 2026
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke (CVA) or TIAStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Heba Abubakr Mohamed Salama, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07358169
- Sponsor's protocol ID
- Mirror therapy
- Status last verified
- Mar 2026
- First submitted
- 4 Jan 2026
- Last updated
- 17 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Mirror Therapy on Motor Recovery and Pain of Hemiparetic Arm Post Stroke: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07358169
- Acronym / sponsor ID
- Mirror therapy
- Conditions
- Stroke (CVA) or TIA, Hemiparesis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 15 Nov 2025 (actual)
- Primary completion
- 15 Feb 2026 (actual)
- Study completion
- Apr 2026 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
evaluate the effect of mirror therapy on motor recovery and pain of hemiparetic arm post stroke
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| control | Other | Other: Controlusual hospitl care |
| mirror group | Experimental | Other: technique, Other: Control |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- First stroke attack (ischemic and haemorrhagic )
- Unilateral stroke with hemiparesis
- Able to understand simple verbal language
Key exclusion criteria (3 listed)
- Severe cognitive impairments.
- Orthopedic or rheumatologic problems restricting upper extremity motor function.
- Contraindications to mirror therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| techniquethe participant performs arm exercise behind mirror | Other | mirror group |
| Controlthe control group receive usual hospital care | Other | control, mirror group |
Primary outcome
Motor Function Assessment
Time frame: 3 weeks
measured by Fugl-Meyer Assessment for upper limb motor function. to describe impairment severity, quantify motor recovery, guide treatment planning, and evaluate outcomes. The scale comprises five domains with a maximum total score of 226 points (Motor 100; Sensation 24; Balance 14; Joint ROM 44; Joint Pain 44). Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226. Points are divided among the domains as follows: Motor score: ranges from 0 (hemiplegia) to 100 points (normal motor performance). Divided into 66 points for upper extremity and 34 points for the lower extremity. Sensation: ranges from 0 to 24 points. Divided into 8 points for light touch and 16 points for position sense. Balance: ranges from 0 to 14 points. Divided into 6 points for sitting and 8 points for standing.
2 secondary outcomes
Functional independence
Time frame: 3 weeks
Pain assessment
Time frame: 3 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
Related trials for Stroke (CVA) or TIA
Not yet recruitingPhase 4
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Recruiting
Pemafibrate for Symptomatic ICAS RCT
Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia
Recruiting
Understanding and Enhancing Human Health and Movement
Spinal Cord Injury, Stroke (CVA) or Transient Ischemic Attack
RecruitingPhase 1/2
Safety and Efficacy of CG-BM1 in Ischemic Stroke
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing technique in people with Stroke (CVA) or TIA and Hemiparesis, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor Function Assessment (time frame: 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.